{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:47:04Z","timestamp":1784861224819,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["BEX1279\/13-0"],"award-info":[{"award-number":["BEX1279\/13-0"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Scientist Training Program","award":["T32GM007739"],"award-info":[{"award-number":["T32GM007739"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vaccination programs have been launched worldwide to halt the spread of COVID-19. However, the identification of existing, safe compounds with combined treatment and prophylactic properties would be beneficial to individuals who are waiting to be vaccinated, particularly in less economically developed countries, where vaccine availability may be initially limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a data-driven approach, combining results from the screening of a large transcriptomic database (L1000) and\u00a0molecular docking analyses, with\u00a0in vitro tests using a lung organoid model of SARS-CoV-2 entry, to identify drugs with putative multimodal properties against COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of thousands of FDA-approved drugs considered, we observed that atorvastatin was the most promising candidate, as its effects negatively correlated with the transcriptional changes associated with infection. Atorvastatin was further predicted to bind to SARS-CoV-2\u2019s main protease and RNA-dependent RNA polymerase, and was shown to inhibit viral entry in our lung organoid model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Small clinical studies reported that general statin use, and specifically, atorvastatin use, are associated with protective effects against COVID-19. Our study corroborrates these findings and\u00a0supports the investigation of atorvastatin in larger clinical studies. Ultimately, our framework demonstrates one promising way to fast-track the identification of compounds for COVID-19, which could similarly be applied when tackling future pandemics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10020-021-00356-6","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T04:02:48Z","timestamp":1631160168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7666-9005","authenticated-orcid":false,"given":"Rodrigo R. R.","family":"Duarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Dennis C.","family":"Copertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis P.","family":"I\u00f1iguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jez L.","family":"Marston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Bram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuibing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas F.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"356_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30195-X","author":"D Baud","year":"2020","unstructured":"Baud D, et al. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis. 2020. https:\/\/doi.org\/10.1016\/S1473-3099(20)30195-X.","journal-title":"Lancet Infect Dis"},{"key":"356_CR2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, et al. Remdesivir for the treatment of COVID-19\u2014final report. N Engl J Med. 2020. 383:1813\u201326.","journal-title":"N Engl J Med"},{"key":"356_CR3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo D, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036\u201345.e1039. https:\/\/doi.org\/10.1016\/j.cell.2020.04.026.","journal-title":"Cell"},{"key":"356_CR4","doi-asserted-by":"publisher","unstructured":"Bowers KJ, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. In: Proceedings of the 2006 ACM\/IEEE conference on supercomputing. 2006. Pp. 43\u201343. https:\/\/doi.org\/10.1109\/SC.2006.54","DOI":"10.1109\/SC.2006.54"},{"key":"356_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2021.1901144","author":"DC Copertino","year":"2021","unstructured":"Copertino DC, et al. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. J Biomol Struct Dyn. 2021a. https:\/\/doi.org\/10.1080\/07391102.2021.1901144.","journal-title":"J Biomol Struct Dyn"},{"key":"356_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/jmv.26299","volume":"93","author":"DC Copertino","year":"2021","unstructured":"Copertino DC, et al. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Med Virol. 2021b;93:187\u20139.","journal-title":"J Med Virol"},{"key":"356_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","volume":"23","author":"SM Corsello","year":"2017","unstructured":"Corsello SM, et al. The drug repurposing hub: a next-generation drug library and information resource. Nat Med. 2017;23:405\u20138.","journal-title":"Nat Med"},{"key":"356_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.amjcard.2020.09.012","volume":"136","author":"LB Daniels","year":"2020","unstructured":"Daniels LB, et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J Cardiol. 2020;136:149\u201355.","journal-title":"Am J Cardiol"},{"key":"356_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","volume":"6","author":"MK DeGorter","year":"2013","unstructured":"DeGorter MK, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6:400\u20138.","journal-title":"Circ Cardiovasc Genet"},{"key":"356_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/10623320500476559","volume":"12","author":"J Dulak","year":"2005","unstructured":"Dulak J, et al. Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005;12:233\u201341.","journal-title":"Endothelium"},{"key":"356_CR11","doi-asserted-by":"publisher","unstructured":"Fidler DP. Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1. In: Negotiating and navigating global health. 2011. Pp. 161\u2013172. https:\/\/doi.org\/10.1371\/journal.pmed.1000247.","DOI":"10.1371\/journal.pmed.1000247"},{"key":"356_CR12","doi-asserted-by":"publisher","first-page":"e01265","DOI":"10.1128\/JVI.01265-20","volume":"94","author":"HM Froggatt","year":"2020","unstructured":"Froggatt HM, Heaton BE, Heaton NS. Development of a fluorescence-based, high-throughput SARS-CoV-2 3CLpro reporter assay. J Virol. 2020;94:e01265\u2013e11220.","journal-title":"J Virol"},{"key":"356_CR13","doi-asserted-by":"publisher","unstructured":"Gao Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020. eabb7498. https:\/\/doi.org\/10.1126\/science.abb7498.","DOI":"10.1126\/science.abb7498"},{"key":"356_CR14","doi-asserted-by":"publisher","first-page":"44219","DOI":"10.1038\/srep44219","volume":"7","author":"H Gbelcov\u00e1","year":"2017","unstructured":"Gbelcov\u00e1 H, et al. Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Sci Rep. 2017;7:44219.","journal-title":"Sci Rep"},{"key":"356_CR15","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.3390\/molecules25215064","volume":"25","author":"M Gendrot","year":"2020","unstructured":"Gendrot M, et al. In vitro antiviral activity of doxycycline against SARS-CoV-2. Molecules. 2020;25:5064.","journal-title":"Molecules"},{"key":"356_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.toxlet.2010.03.015","volume":"196","author":"R Gminski","year":"2010","unstructured":"Gminski R, Tang T, Mersch-Sundermann V. Cytotoxicity and genotoxicity in human lung epithelial A549 cells caused by airborne volatile organic compounds emitted from pine wood and oriented strand boards. Toxicol Lett. 2010;196:33\u201341.","journal-title":"Toxicol Lett"},{"key":"356_CR18","doi-asserted-by":"publisher","unstructured":"Guan W-J, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020a. 55(5). https:\/\/doi.org\/10.1183\/13993003.00547-2020.","DOI":"10.1183\/13993003.00547-2020"},{"key":"356_CR17","doi-asserted-by":"publisher","unstructured":"Guan W-J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020b. 382(18). https:\/\/doi.org\/10.1056\/NEJMoa2002032.","DOI":"10.1056\/NEJMoa2002032"},{"key":"356_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2901-9","volume":"589","author":"Y Han","year":"2020","unstructured":"Han Y, et al. Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature. 2020;589:270\u20135.","journal-title":"Nature"},{"key":"356_CR20","unstructured":"IMS Institute for Healthcare Informatics. Medicine Use and Spending Shifts: a review of the use of medicines in the U.S. in 2014. 2015. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/medicines-use-and-spending-shifts-in-the-us-in-2014.pdf. Accessed 24 Feb 2021."},{"key":"356_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30068-1","volume":"8","author":"Y Ji","year":"2020","unstructured":"Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob Health. 2020;8: e480.","journal-title":"Lancet Glob Health"},{"key":"356_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-biodatasci-072018-021211","volume":"2","author":"AB Keenan","year":"2019","unstructured":"Keenan AB, et al. Connectivity mapping: methods and applications. Annu Rev Biomed Data Sci. 2019;2:69\u201392.","journal-title":"Annu Rev Biomed Data Sci"},{"key":"356_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/ci800298z","volume":"49","author":"O Korb","year":"2009","unstructured":"Korb O, Stutzle T, Exner TE. Empirical scoring functions for advanced protein-ligand docking with PLANTS. J Chem Inf Model. 2009;49:84\u201396.","journal-title":"J Chem Inf Model"},{"key":"356_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.cmet.2011.03.020","volume":"13","author":"SD Kunkel","year":"2011","unstructured":"Kunkel SD, et al. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab. 2011;13:627\u201338.","journal-title":"Cell Metab"},{"key":"356_CR25","unstructured":"Shen L, Sinai ISoMaM. GeneOverlap: test and visualize gene overlaps. R package version 1.28.0, http:\/\/shenlab-sinai.github.io\/shenlab-sinai\/. 2021."},{"key":"356_CR26","doi-asserted-by":"publisher","first-page":"27580","DOI":"10.18632\/oncotarget.4768","volume":"6","author":"W-Y Lee","year":"2015","unstructured":"Lee W-Y, et al. Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1. Oncotarget. 2015;6:27580\u201395.","journal-title":"Oncotarget"},{"key":"356_CR27","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cell.2015.05.011","volume":"161","author":"J Liu","year":"2015","unstructured":"Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell. 2015;161:999\u20131011.","journal-title":"Cell"},{"key":"356_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/B978-141605469-6.50026-3","volume-title":"Clinical lipidology","author":"JM McKenney","year":"2009","unstructured":"McKenney JM, Ganz P, Wiggins BS, Saseen JS. CHAPTER 22\u2014statins. In: Ballantyne CM, editor. Clinical lipidology. Philadelphia: W.B. Saunders; 2009. p. 253\u201380."},{"key":"356_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1046\/j.1365-2249.2003.02021.x","volume":"131","author":"G Neurauter","year":"2003","unstructured":"Neurauter G, et al. Atorvastatin suppresses interferon-gamma-induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines. Clin Exp Immunol. 2003;131:264\u20137.","journal-title":"Clin Exp Immunol"},{"key":"356_CR30","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680\u20136.","journal-title":"Emerg Microbes Infect"},{"key":"356_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4683","author":"G Onder","year":"2020","unstructured":"Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.4683.","journal-title":"JAMA"},{"key":"356_CR32","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.12.246389","author":"KH Risner","year":"2020","unstructured":"Risner KH, et al. Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.08.12.246389","journal-title":"bioRxiv"},{"key":"356_CR33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13054-020-03154-4","volume":"24","author":"G Rodriguez-Nava","year":"2020","unstructured":"Rodriguez-Nava G, et al. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care. 2020;24:429.","journal-title":"Crit Care"},{"key":"356_CR34","doi-asserted-by":"publisher","first-page":"Ii18","DOI":"10.1161\/01.CIR.0000129505.34151.23","volume":"109","author":"U Sch\u00f6nbeck","year":"2004","unstructured":"Sch\u00f6nbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109:Ii18-26.","journal-title":"Circulation"},{"key":"356_CR35","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149\u201358.","journal-title":"Lancet"},{"key":"356_CR36","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","volume":"72","author":"TU Singh","year":"2020","unstructured":"Singh TU, et al. Drug repurposing approach to fight COVID-19. Pharmacol Rep. 2020;72:1479\u2013508.","journal-title":"Pharmacol Rep"},{"key":"356_CR37","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"356_CR38","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171:1437-1452 e1417.","journal-title":"Cell"},{"key":"356_CR39","doi-asserted-by":"publisher","first-page":"17458","DOI":"10.1038\/s41598-020-74492-0","volume":"10","author":"WYT Tan","year":"2020","unstructured":"Tan WYT, Young BE, Lye DC, Chew DEK, Dalan R. Statin use is associated with lower disease severity in COVID-19 infection. Sci Rep. 2020;10:17458.","journal-title":"Sci Rep"},{"key":"356_CR40","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"The RECOVERY Collaborative Group","year":"2021","unstructured":"The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19\u2014preliminary report. N Engl J Med. 2021; 384:693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","journal-title":"N Engl J Med"},{"key":"356_CR41","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","volume":"169","author":"MA Whitt","year":"2010","unstructured":"Whitt MA. Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods. 2010;169:365\u201374.","journal-title":"J Virol Methods"},{"key":"356_CR42","unstructured":"WHO. Coronavirus disease (COVID-19): dexamethasone. https:\/\/www.who.int\/news-room\/q-a-detail\/coronavirus-disease-covid-19-dexamethasone. Accessed 19 Feb 2021."},{"key":"356_CR43","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(20)30763-7","volume":"395","author":"G Yamey","year":"2020","unstructured":"Yamey G, et al. Ensuring global access to COVID-19 vaccines. Lancet. 2020;395:1405\u20136.","journal-title":"Lancet"},{"key":"356_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.stem.2020.06.015","volume":"27","author":"L Yang","year":"2020","unstructured":"Yang L, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27:125\u201336.e127.","journal-title":"Cell Stem Cell"},{"key":"356_CR45","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.01.433498","author":"MI Zapata-Cardona","year":"2021","unstructured":"Zapata-Cardona MI, et al. Atorvastatin effectively inhibits late replicative cycle steps of SARS-CoV-2 in vitro. bioRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.03.01.433498","journal-title":"bioRxiv"},{"key":"356_CR46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/17476348.2018.1457437","volume":"12","author":"AA Zeki","year":"2018","unstructured":"Zeki AA, Elbadawi-Sidhu M. Innovations in asthma therapy: is there a role for inhaled statins? Expert Rev Respir Med. 2018;12:461\u201373.","journal-title":"Expert Rev Respir Med"},{"key":"356_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb3405","author":"L Zhang","year":"2020","unstructured":"Zhang L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science. 2020a. https:\/\/doi.org\/10.1126\/science.abb3405.","journal-title":"Science (new York, NY)."},{"key":"356_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235458","volume":"15","author":"B Zhang","year":"2020","unstructured":"Zhang B, et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS ONE. 2020b. 15: e0235458.","journal-title":"PLoS ONE"},{"key":"356_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cmet.2020.06.015","volume":"32","author":"X-J Zhang","year":"2020","unstructured":"Zhang X-J, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020c. 32:176\u201387.e174.","journal-title":"Cell Metab"},{"key":"356_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105078","volume":"190","author":"J Zhao","year":"2021","unstructured":"Zhao J, et al. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res. 2021;190: 105078.","journal-title":"Antiviral Res"},{"issue":"W1","key":"356_CR51","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/nar\/gkz401","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao Y, et al. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Research. 2019;47(W1), W199\u2013W205.","journal-title":"Nucleic Acids Research"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-021-00356-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-021-00356-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-021-00356-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T13:52:12Z","timestamp":1633355532000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.1186\/s10020-021-00356-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["356"],"URL":"https:\/\/doi.org\/10.1186\/s10020-021-00356-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.12148764.v1","asserted-by":"object"}]},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]},"assertion":[{"value":"2 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We change to bold all values smaller than -80 in Table 1","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RES is on the scientific advisory board of Miromatrix Inc. and is a consultant and speaker for Alnylam Inc. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}